0.5500
25-November-24 16:45:01
15 minutes delayed
Stocks
9.9999999999989E-05
+0.02%
Today's range
0.5410 - 0.5728
ISIN
N/A
Source
NASDAQ
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
08 Nov 2024 06:00:00 By Nasdaq GlobeNewswire
AlloVir Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy
22 Dec 2023 07:00:00 By Nasdaq GlobeNewswire